Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 361

1.

Failure to achieve a threshold dose of CD34+ CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation.

Sartor MM, Garvin F, Antonenas V, Bradstock KF, Gottlieb DJ.

Bone Marrow Transplant. 2007 Nov;40(9):851-7. Epub 2007 Aug 20.

PMID:
17704793
2.

Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.

Wallington-Beddoe CT, Gottlieb DJ, Garvin F, Antonenas V, Sartor MM.

Biol Blood Marrow Transplant. 2009 Nov;15(11):1386-93. doi: 10.1016/j.bbmt.2009.06.018. Epub 2009 Aug 19.

3.

The impact of CD34+ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation.

Chang YJ, Xu LP, Liu DH, Liu KY, Han W, Chen YH, Wang Y, Chen H, Wang JZ, Zhang XH, Zhao XY, Huang XJ.

Pediatr Blood Cancer. 2009 Dec;53(6):1100-6. doi: 10.1002/pbc.22159.

PMID:
19743519
4.

High-dose CD34+ cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose.

Lefrère F, Delarue R, Somme D, Levy V, Damaj G, Tu A, Porcher R, Audat F, Boulat C, Cavazzana-Calvo M, Buzyn A, Belanger C, Maillard N, Hermine O, Varet B.

Transfusion. 2002 Apr;42(4):443-50.

PMID:
12076291
5.

Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status.

Chang YJ, Xu LP, Liu DH, Liu KY, Han W, Chen YH, Yu-Wang, Chen H, Wang JZ, Zhang XH, Zhao XY, Huang XJ.

Biol Blood Marrow Transplant. 2009 May;15(5):632-8. doi: 10.1016/j.bbmt.2009.02.001.

6.

Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation.

Meldgaard Knudsen L, Jensen L, Jarlbaek L, Hansen PG, Hansen SW, Drivsholm L, Nikolaisen K, Gaarsdal E, Johnsen HE.

Haematologica. 1999 Jun;84(6):517-24.

8.

Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation.

Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland DR, Chin-Yee IH.

Bone Marrow Transplant. 2002 Jun;29(12):967-72.

9.

Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count.

Bolwell BJ, Goormastic M, Andresen S, Overmoyer B, Pohlman B, Kalaycio M.

Bone Marrow Transplant. 1997 Sep;20(6):459-63.

11.

High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.

Gunn N, Damon L, Varosy P, Navarro W, Martin T, Ries C, Linker C.

Biol Blood Marrow Transplant. 2003 Oct;9(10):643-8.

12.

Post-thaw viable CD34(+) cell count is a valuable predictor of haematopoietic stem cell engraftment in autologous peripheral blood stem cell transplantation.

Lee S, Kim S, Kim H, Baek EJ, Jin H, Kim J, Kim HO.

Vox Sang. 2008 Feb;94(2):146-52. Epub 2007 Nov 19.

PMID:
18028260
13.

The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue.

Millar BC, Millar JL, Shepherd V, Blackwell P, Porter H, Cunningham D, Judson I, Treleaven J, Powles RL, Catovsky D.

Bone Marrow Transplant. 1998 Sep;22(5):469-75.

14.

CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of cells at 4 degrees C does not affect outcome.

Lazarus HM, Pecora AL, Shea TC, Koç ON, White JM, Gabriel DA, Cooper BW, Gerson SL, Krieger M, Sing AP.

Bone Marrow Transplant. 2000 Mar;25(5):559-66.

15.

Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation.

Kamel AM, El-Sharkawy N, Mahmoud HK, Khalaf MR, El Haddad A, Fahmy O, El Fattah RA, Sayed D.

Bone Marrow Transplant. 2005 Jan;35(2):129-36.

PMID:
15568034
16.

Impact of mobilized blood progenitor cell quality determined by the CFU-GM/CD34+ ratio on rapid engraftment after blood stem cell transplantation.

Fu SQ, Abboud CN, Brennan JK, Ifthikharuddin JJ, Nichols D, Liesveld JL.

Blood Cells Mol Dis. 2002 May-Jun;28(3):315-21.

PMID:
12367578
17.

CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.

Kasow KA, Sims-Poston L, Eldridge P, Hale GA.

Biol Blood Marrow Transplant. 2007 May;13(5):608-14. Epub 2007 Mar 23.

18.

The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cells as well as the total CD34+ cell dose.

Stewart DA, Guo D, Luider J, Auer I, Klassen J, Morris D, Chaudhry A, Brown C, Russell JA, Gluck S.

Bone Marrow Transplant. 2000 Feb;25(4):435-40.

19.

Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.

Michallet M, Philip T, Philip I, Godinot H, Sebban C, Salles G, Thiebaut A, Biron P, Lopez F, Mazars P, Roubi N, Leemhuis T, Hanania E, Reading C, Fine G, Atkinson K, Juttner C, Coiffier B, Fière D, Archimbaud E.

Exp Hematol. 2000 Jul;28(7):858-70.

PMID:
10907648
20.

Supplemental Content

Support Center